

165-
TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
DI-4389 US DIV


In Re Application Of: Martis et al.

PHZ

Serial No.	Filing Date	Examiner	Group Art Unit
09/909,733	June 20, 2001	Unknown	Unassigned

Title:

IMPROVED PERITONEAL DIALYSIS SOLUTIONS WITH POLYPEPTIDES



Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
DI-4389 US DIV

In Re Application: Martis et al.

Serial No. 09/909,733	Filing Date June 20, 2001	Examiner Unknown	Group Art Unit Unassigned
--------------------------	------------------------------	---------------------	------------------------------

IMPROVED PERITONEAL DIALYSIS SOLUTIONS WITH POLYPEPTIDES



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited
9/26/01 with the U.S. Postal Service
as first class mail under 37 C.F.R. 1.8 and is
addressed to the Assistant Commissioner for Patents,
Washington, D.C. 20231

Signature of Person Mailing Correspondence

Robert J. Buccieri

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by
deposit account.

Signature

Dated: September 26, 2001

Robert M. Barrett
Bell, Boyd & Lloyd LLC
P.O. Box 1135
Chicago, Illinois 60690-1135

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Martis et al
Application No. : 09/909,733
Filed : June 20, 2001
Title : IMPROVED PERITONEAL DIALYSIS SOLUTIONS WITH POLYPEPTIDES
Group Art Unit : Unassigned
Examiner : Unassigned
Docket No. : DI-4389 US DIV

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

SIR:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, copies of which can be found in the parent, application no. 07/995,106, filed on December 22, 1992, be made during the course of examination of the above-identified application for United States patent.

U.S. Patent Number	Issue Date	Name
3,939,261	02/17/76	Barth
4,168,337	12/18/79	Gordon
4,179,338	12/18/79	Gordon
4,309,417	01/05/82	Staples
4,361,587	11/30/82	Brule et al.
4,448,716	05/15/84	Tsau
4,604,379	08/05/86	Twardowski et al.
4,614,657	09/30/86	Shent et al.
4,631,211	12/23/86	Houghten
4,761,237	08/02/88	Alexnder et al.
4,886,789	12/12/89	Milner
4,906,616	03/06/90	Gilchrist et al.
4,959,175	09/25/90	Yatzidis
5,010,175	04/23/91	Rutter et al.
5,011,826	04/30/91	Steudle et al.
5,039,609	08/13/91	Klein
5,053,393	10/01/91	Tjoeng et al.

U.S. Patent Number	Issue Date	Name
5,100,875	03/31/92	Marguerie de Rotrou
5,182,366	01/26/93	Huebner et al.
5,192,746	03/09/93	Lobl et al.
5,211,643	05/18/93	Reinhardt et al.

Foreign Documents

Patent Number	Publication Date	Country
0 399 549	11/28/90	Europe
0431 465 A1	06/12/91	Europe
0 076 355	04/13/83	Europe
0 153 164	08/28/85	Europe
0 170 275	02/05/86	Europe
0 218 900	01/22/92	Europe
0 270 545	09/26/90	Europe
0 564 672 A1	10/13/93	Europe
0 277 868 A3	12/19/90	Europe
WO 87/03786	07/02/87	PCT
WO 93/19792	10/14/93	PCT

OTHER DOCUMENTS

The Merck Index, Item 4353 (11th ed., Merck & Co. 1989)


Van Holde, Physical Biochemistry, Prentice Hall, 1971, pp 26-30 and pp 38-47.

REMARKS

Applicants look forward to early and favorable consideration of this matter.

Date: September 26, 2001

Respectfully submitted,


 Robert M. Barrett
 Registration No. 30,142
 Bell, Boyd & Lloyd LLC
 P.O. Box 1135
 Chicago, IL 60690-1135
 Phone: (312) 807-4204
 Attorney for Applicants